Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04094948
Other study ID # Pro00102462
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date January 1, 2023
Est. completion date December 30, 2025

Study information

Verified date August 2022
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goals of this study are to determine safety and efficacy with regard to motor function of oral clenbuterol in combination with ERT in subjects with LOPD


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 30, 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Diagnosis of Pompe disease by blood Acid alpha-glucosidase (GAA) assay and GAA gene sequencing, 2. Age: 18+ years at enrollment, 3. Receiving enzyme replacement therapy (ERT) at a stable dose for >104 weeks, 4. FVC >15% of expected (supine). 5. Subjects are capable of giving written consent. 6. Able to walk at least 100 meters on the 6 minute walk test (6MWT) (with assistive devices permitted). Exclusion Criteria: 1. Continuous invasive ventilation (via tracheostomy or endotracheal tube) 2. 6MWT distance >90% of expected performance (% expected) 3. FVC >90% of expected (upright). 4. Clinically relevant illness within two weeks of enrollment including fever > 38.2o C, vomiting more than once in 24 hours, seizure, or other symptom deemed contraindicative to new therapy. 5. Chronic heart disease (Myocardial infarction, arrythmia, cardiomyopathy) 6. Tachycardia 7. History of seizure disorder 8. Hyperthyroidism 9. Pheochromocytoma 10. Pregnancy 11. History of diabetes 12. History of hypersensitivity to ß2-agonist drugs such as albuterol, levalbuterol (Xopenex), bitolterol (Tornalate), pirbuterol (Maxair), terbutaline, salmeterol (Serevent), 13. Patients on a non-standard schedule for ERT; for example, weekly infusions as opposed to infusions every two weeks. 14. Treatment for asthma in the previous 12 months. 15. Renal insufficiency (elevated serum creatinine). 16. Having started respiratory muscle strength training in the last 6 months prior to study day 1 or having discontinued respiratory muscle strength training in the 6-month period preceding study day 1, or having started respiratory strength training greater than 6 months prior to study day 1 and unwilling to continue for the first year of study participation. 17. Received an investigational drug or participated in another interventional study within 90 days of Study Day 1. 18. Anti-rhGAA IgG with sustained titer >1:25.600 for >6 months at time of enrollment. 19. The use of the following concommitant meds is prohibited during the study: - diuretics (water pill); - digoxin (digitalis, Lanoxin); - beta-blockers such as atenolol (Tenormin), metoprolol (Lopressor), and propranolol (Inderal); - tricyclic antidepressants such as amitriptyline (Elavil, Etrafon), doxepin (Sinequan), imipramine (Janimine, Tofranil), and nortriptyline (Pamelor); - Monoamine oxidase (MAO) inhibitors such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate); or - other bronchodilators such as albuterol, levalbuterol (Xopenex), bitolterol (Tornalate), pirbuterol (Maxair), terbutaline (Brethine, Bricanyl), salmeterol (Serevent), isoetherine (Bronkometer), metaproterenol (Alupent, Metaprel), or isoproterenol (Isuprel Mistometer).

Study Design


Intervention

Drug:
Clenbuterol
20 mcg spiropent tablets will be overencapsulated (two 20 mcg tablets per capsule)
Placebos
dextrose-filled capsules

Locations

Country Name City State
United States Duke University Medical Center Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in 6 minute walk test (MWT) distance Baseline (week 0) through 52 weeks
Secondary Changes in pulmonary function tests: forced expiratory volume in 1 second (FEV1) Baseline (week 0) through 52 weeks
Secondary Changes in pulmonary function tests: forced vital capacity (FVC) Baseline (week 0) through 52 weeks
Secondary Changes in pulmonary function tests: maximum expiratory pressure (MEP) Baseline (week 0) through 52 weeks
Secondary Changes in pulmonary function tests: Maximum inspiratory pressure (MIP) Baseline (week 0) through 52 weeks
Secondary Changes in graded functional test: Gait, Stairs, Gower, Chair (GSCS) Baseline (week 0) through 52 weeks
Secondary Changes in graded functional test: Quick Motor Function Test (QMFT) Baseline (week 0) through 52 weeks
Secondary Changes in the concentration of alanine transaminase (ALT) in serum Avoidance of liver toxicity as defined by a a persistent (sustained >2 weeks) >3x increase in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) from the respective baseline values and/or an increase in direct, indirect or total bilirubin of >3x the upper limit of normal (no liver toxicity has been reported in association with clenbuterol administration and therefore repeat testing should be acceptable) Baseline (week 0) through 52 weeks
Secondary Changes in the concentration of creatine kinase (CK) in serum Avoidance of Worsening muscle involvement (i.e. muscle weakness, cramping, or fatigue) accompanied by a persistent (sustained >2 weeks) >3x increase in CK from baseline that is >2x the upper limit of normal (elevated CK is associated with LOPD and minor elevations of CK have been reported in association with clenbuterol administration, therefore repeat testing should be acceptable). Baseline (week 0) through 52 weeks
Secondary Changes in the concentration of urinary glucose tetramer (Glc4) Baseline (week 0) through 52 weeks
See also
  Status Clinical Trial Phase
Completed NCT00158600 - A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease Phase 3
Recruiting NCT04174105 - Gene Transfer Study in Patients With Late Onset Pompe Disease Phase 1/Phase 2
Active, not recruiting NCT04093349 - A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE) Phase 1/Phase 2
Completed NCT03285126 - Pompe Gene Therapy- Screening for Eligibility
Recruiting NCT05083806 - MSOT in Pompe Disease N/A
Recruiting NCT05272969 - Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
Active, not recruiting NCT03694561 - Developing a Management Approach for Patients With "Late-Onset" Pompe Disease
Completed NCT00455195 - Late-Onset Treatment Study Extension Protocol Phase 4
Completed NCT00731081 - Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving Myozyme® N/A
Recruiting NCT05951790 - Inspiratory Muscle Training (IMT) in Adult People With Pompe Disease N/A
Completed NCT01288027 - Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa Phase 4
Recruiting NCT00567073 - Pompe Pregnancy Sub-Registry
Completed NCT03893240 - Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease N/A
Completed NCT00250939 - A Study of rhGAA in Patients With Late-Onset Pompe Disease Phase 2
Recruiting NCT03911505 - ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD Phase 3
Recruiting NCT06150820 - A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease N/A
Completed NCT03729362 - A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease Phase 3
Not yet recruiting NCT06178432 - Evaluation of the Safety, Tolerability and Efficacy of Gene Therapy Drug for Late Onset Pompe Disease (LOPD) Early Phase 1
Completed NCT00268944 - Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support Phase 3
Active, not recruiting NCT04138277 - A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD Phase 3